Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TScan Therapeutics, Inc. - Common Stock (NQ:TCRX)

1.470 -0.040 (-2.65%)
Streaming Delayed Price Updated: 11:20 AM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 127,278
Open 1.510
Bid (Size) 1.450 (30)
Ask (Size) 1.470 (3)
Prev. Close 1.510
Today's Range 1.450 - 1.550
52wk Range 1.020 - 7.890
Shares Outstanding 23,976,942
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
What Analysts Are Saying About TScan Therapeutics Stock
Via Benzinga

Performance

YTD
-52.4%
-52.4%
1 Month
-18.3%
-18.3%
3 Month
+16.7%
+16.7%
6 Month
-50.7%
-50.7%
1 Year
-74.7%
-74.7%

More News

Read More
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
Breaking Down TScan Therapeutics: 4 Analysts Share Their Views
Via Benzinga
The Analyst Landscape: 5 Takes On TScan Therapeutics
Via Benzinga
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
Via Benzinga
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
From TScan Therapeutics, Inc.
Via GlobeNewswire
Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews
Via Benzinga
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
Via Benzinga
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Is TScan Therapeutics Stock Gaining Today?
Via Benzinga
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in Upcoming Investor Conferences
From TScan Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is TScan Therapeutics, Inc. - Common Stock publicly traded?
Yes, TScan Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does TScan Therapeutics, Inc. - Common Stock trade on?
TScan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for TScan Therapeutics, Inc. - Common Stock?
The ticker symbol for TScan Therapeutics, Inc. - Common Stock is TCRX on the Nasdaq Stock Market
What is the current price of TScan Therapeutics, Inc. - Common Stock?
The current price of TScan Therapeutics, Inc. - Common Stock is 1.470
When was TScan Therapeutics, Inc. - Common Stock last traded?
The last trade of TScan Therapeutics, Inc. - Common Stock was at 07/07/25 11:20 AM ET
What is the market capitalization of TScan Therapeutics, Inc. - Common Stock?
The market capitalization of TScan Therapeutics, Inc. - Common Stock is 35.25M
How many shares of TScan Therapeutics, Inc. - Common Stock are outstanding?
TScan Therapeutics, Inc. - Common Stock has 35M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.